Vmn2r115 Inhibitors
Vmn2r115 inhibitors belong to a specialized category of chemical agents that interact with specific olfactory receptors, which are proteins located on the cell membranes of olfactory sensory neurons. These receptors are part of a broader class known as vomeronasal type-2 receptors (V2Rs), which are implicated in the detection of pheromones and other chemical signals that can have an impact on social and reproductive behaviors in various species. The Vmn2r115 subtype is one of many V2Rs, and molecules that specifically inhibit this receptor are designed to interfere with its normal function. Inhibition occurs through a complex interaction at the molecular level; these inhibitors bind to the receptor in a way that prevents the normal ligand (such as a pheromone) from attaching to it and initiating the usual cellular response.
The design of Vmn2r115 inhibitors is a nuanced process that requires a deep understanding of the receptor's structure and the mechanics of its interaction with various ligands. These inhibitors may be discovered through high-throughput screening of chemical libraries, rational drug design, or by studying the structure-activity relationship (SAR) of known ligands. The chemical structures of these inhibitors can vary widely, but they typically possess functional groups that allow them to interact with specific amino acids within the receptor's binding site. The interaction can be competitive, where the inhibitor and the natural ligand vie for the same binding site, or non-competitive, where the inhibitor binds to a different part of the receptor and induces a conformational change that reduces the receptor's affinity for its natural ligand. By blocking or modulating the receptor's ability to bind to its natural ligand, these inhibitors essentially 'silence' the receptor's function, providing a tool for understanding the biochemical pathways and mechanisms through which the Vmn2r115 receptor operates.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
As a tyrosine kinase inhibitor, afatinib blocks signaling through the ERBB network. Vmn2r115, as a chemosensory receptor, could rely on downstream ERBB signaling for proper function. Inhibition of this pathway by afatinib may reduce the functional activity of Vmn2r115 by limiting its signaling capacity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, impedes the PI3K/Akt pathway. If Vmn2r115 signaling involves PI3K/Akt pathway activation, this compound would indirectly diminish Vmn2r115's functional activity by blocking its downstream signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As an MEK inhibitor, PD98059 specifically inhibits the MAPK/ERK pathway. If Vmn2r115 utilizes this pathway for signal transduction, PD98059 would lead to decreased signaling and thus functional inhibition of Vmn2r115. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway, which is crucial for cell growth and metabolism. If Vmn2r115's function is tied to mTOR pathway activity, rapamycin may result in diminished Vmn2r115 activity through these mechanisms. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
An inhibitor of p38 MAPK, SB203580 would prevent signaling through the p38 MAPK pathway. If Vmn2r115 is involved in this signaling route, its activity could be indirectly diminished by SB203580's action. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 selectively inhibits MEK1/2 and therefore the ERK pathway. Inhibition of this pathway could lead to reduced signaling of Vmn2r115 if it is functionally connected to ERK pathway activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By blocking PI3K, this compound would disrupt any PI3K-dependent signaling pathways potentially utilized by Vmn2r115, leading to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 would suppress the JNK pathway. If Vmn2r115's signaling relies on JNK activation, this compound would result in a decrease in Vmn2r115 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase. By inhibiting EGFR, gefitinib may indirectly affect Vmn2r115 activity if the receptor's function is associated with EGFR signaling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
This dual inhibitor targets both EGFR and HER2 tyrosine kinases, potentially impacting pathways Vmn2r115 may use. Thus, lapatinib might decrease Vmn2r115 function by inhibiting relevant tyrosine kinase signaling. | ||||||